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CardioprotectionThe utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of cardiotoxicity.
It has been calculated that approximately 10% of patients treated with doxorubicin or its derivatives will
develop cardiac complications up to 10 years after the cessation of chemotherapy. Oxidative stress has
been established as the primary cause of cardiotoxicity. However, interventions reducing oxidative stress
have not been successful at reducing the incidence of cardiotoxicity in patients treated with doxorubicin.
New insights into the cardiomyocyte response to oxidative stress demonstrate that underlying differences
between in vitro and in vivo toxicities may modulate the response to superoxide radicals and related com-
pounds. This has led to potentially new uses for pre-existing drugs and new avenues of exploration to ﬁnd
better pharmacotherapies and interventions for the prevention of cardiotoxicity. However, much work still
must be done to validate the clinical utility of these new approaches and proposed mechanisms. In this
review, the authors have reviewed the molecular mechanisms of the pathogenesis of acute and chronic
doxorubicin-induced cardiotoxicity and propose potential pharmacological interventions and treatment
options to prevent or reverse this speciﬁc type of heart failure.
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Doxorubicin is a secondarymetabolite of Streptomyces peucetius var.
Caesius, along with daunorubicin, epirubicin, and idarubicin, and be-
longs to the family of anthracyclines. These are well-established and
highly effective anti-neoplastic agents, used to treat several adult and
pediatric cancers, such as solid tumors, leukemia, lymphomas and
breast cancer. The successful use of doxorubicin has been hampered
by toxicities such as hematopoietic suppression, nausea, vomiting, ex-
travasation, and alopecia, yet the most feared side-effect is cardiotoxi-
city. The onset of this cardiotoxicity may be delayed until as many as
10–15 years after cessation of chemotherapy. It is characterized by a
broad spectrum of symptoms ranging from asymptomatic electrocardi-
ography (ECG)-changes, to pericarditis and decompensated cardiomy-
opathy. While the probability of developing cardiomyopathy is largely
dose-dependent [1], cardiotoxicity may occur at low doses due to in-
creased individual susceptibility [2].
Gender difference has been mentioned as one of the risk factors in
the toxic effects of doxorubicin. Lipshultz SE et al. [3] reported that
female had more severe cardiotoxicity with more depressed contrac-
tility. Several other groups demonstrated also a signiﬁcant higher
risk in subclinical cardiotoxicity in female compared with male by
using multivariate analysis [4–6]. Another risk factor is age, for exam-
ple, elders older than 65 years or children younger than 4 years are at
an increased risk [7–9] for doxorubicin-induced cardiotoxicity. Simul-
taneous administration of other cardiotoxic drugs, mediastinal radio-
therapy, and cumulative dose of doxorubicin can correlate with an
increased risk of doxorubicin-induced cardiomyopathy [2]. In addi-
tion, chronic conditions such as hypertension, diabetes mellitus,
liver disease, and previous cardiac disease can also contribute to an
increased risk of cardiotoxicity [8]. It should be noted that at least
one epidemiological study has disputed the validity of these risk fac-
tors [10]. Earlier investigations tend to use clinical symptoms of heart
failure as their end point [11], while more recent studies use a variety
of functional and biochemical endpoints, such as decreased ejection
fraction or cardiac troponin-T measurements, to deﬁne doxorubicin-
induced cardiomyopathy [10].
Since the deleterious effects of doxorubicin on the heart are often
not detected until years after cessation of the chemotherapy [7,12], the
greatest impact is on pediatric cancer survivors. About 60% of pediatric
cancer patients will be given an anthracycline [13] and 10% of these
patients will develop symptomatic cardiomyopathy up to 15 years
after the end of chemotherapy [8]. The difference in time-of-onset sug-
gests that different mechanisms may be involved in doxorubicin-
induced cardiomyopathy. Treatment protocols to protect the heart with-
out diminishing the drug's anti-tumor activity are urgently needed. In
this review we explore the molecular mechanisms of doxorubicin-
induced cardiotoxicity and provide an extensive overview of current
and potential pharmacological interventions and treatment options to
prevent or reverse this speciﬁc type of heart failure.2. Molecular mechanism
Multiple mechanisms are involved in doxorubicin induced heart
failure. Doxorubicin-induced cardiomyopathy is strongly linked to
an increase in cardiac oxidative stress, as evidenced by reactiveoxygen species (ROS) induced damage such as lipid peroxidation,
alongwith reduced levels of antioxidants and sulfhydryl groups. Myoﬁ-
brillar deterioration and intracellular calcium dysregulation are also im-
portant mechanisms commonly associated with doxorubicin-induced
cardiac toxicity. Not only are cardiomyocytes a target of doxorubicin in-
duced apoptosis, but endothelial cells are also affected, as indicated by
caspase activation and internucleosomal DNA degradation. Further-
more, the cardiac toxicity associated with doxorubicin administration
is mediated, at least in part, by changes in the high-energy phosphate
pool, endothelin-1 levels, and disturbances of myocardial adrenergic
signaling. All of these molecular mechanisms of cardiotoxicity are
explored in greater detail below.
2.1. Oxidative stress
The induction of free radical production is the best described
major mechanism through which doxorubicin injures the myocardi-
um [14–16]. The heart's unique vulnerability to oxidative stress [17]
has given this aspect of doxorubicin-induced cardiomyopathy an
overwhelming prominence in the literature. Over the past thirty
years, the understanding of how free radicals are generated and
how they damage the heart has evolved from a purely chemical reac-
tion to a molecular understanding of how enzymes such as nitric
oxide synthases (NOS) and NAD(P)H oxidase interact with doxorubi-
cin and induce oxidative stress.
2.1.1. Mitochondrial dependent ROS
The mitochondria are the most extensively and progressively in-
jured subcellular organelles of doxorubicin-induced cardiotoxicity.
One reason for this may be due to the fact that the cationic drug
doxorubicin is retained in the mitochondrial inner membrane by
forming a nearly-irreversible complex with cardiolipin [18]. The pro-
teins of the electron-transport chain require cardiolipin binding to
function properly, and it has been argued that since doxorubicin dis-
rupts the cardiolipin–protein interface, more superoxide (O2−) forma-
tion occurs [19]. Other membrane proteins, such as those responsible
for the transfer of carnitine, can also be adversely affected by doxoru-
bicin, contributing to the decrease in mitochondrial function [20]. It is
quite plausible that these events disrupt mitochondrial (and there-
fore cellular) metabolism, since mitochondria produce more than
90% of the ATP utilized by cardiomyocytes [21]. This functional
disruption leads to ultrastructural pathologic changes such as mito-
chondrial swelling and myelin ﬁgures within the mitochondria [22].
However, the studies showing doxorubicin-induced myocardial
dysfunction were often performed with supraclinical concentrations
of doxorubicin [23,24]. Yet clinical doses of doxorubicin can also
directly affect mitochondrial function, but the effects are less severe.
In a rat model of chronic doxorubicin-induced cardiomyopathy, it
was found that long-chain-fatty acid oxidation in cardiac mitochon-
dria is signiﬁcantly decreased, while glucose metabolism is increased,
indicating an overall shift from an aerobic to anaerobic metabolic
state [25]. Although this shift in metabolism is a common feature of
heart failure, doxorubicin induced oxidative stress could induce
signaling to cause the shift in metabolism from long-chain fatty acid
metabolism to glucose when metabolic genes are transcriptionally
suppressed.
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mitochondrial gene expression. This group used transgenic mito-
chondrial reporter mice to demonstrate that doxorubicin suppresses
cardiac mitochondrial metabolism and biogenesis, resulting in apo-
ptosis. This could be reversed by allowing the mice to inhale low
levels of carbon monoxide (CO), which activates the genes required
for mitochondrial biosynthesis and by upregulating levels of nuclear
encoded heme oxygenase (HO). This indicates that doxorubicin also
interferes with both nuclear and mitochondrial transcriptional regu-
lation [27].
Upregulation of manganese superoxide dismutase (MnSOD) has
been shown to enhance cell survival in the presence of doxorubicin
through its role as a free radical scavenger in mitochondria [28]. The
compound calceolarioside protects from Dox-induced apoptosis by
upregulation of several superoxide dismutases (SOD) and heme
oxygenase, and preserving mitochondrial membrane potential [29].
In addition, overexpression of Gpx1, a cytosolic and mitochondrial
enzyme that reduces hydrogen peroxide (H2O2) and fatty acid hydro-
peroxides, protects mice hearts against acute doxorubicin-induced
cardiotoxicity and prevents impairment of mitochondrial respiration
and inhibition of complex I activity [30].
It is well-known that mitochondria play an important role in
the pathogenesis of doxorubicin-induced cardiomyopathy. Preven-
tion of mitochondria dysfunction will prevent myocardial alteration
and subsequently make better cardiac outcome. However, further
experiments to unravel speciﬁc function of mitochondria in this path-
ogenesis are needed.
2.1.2. NOS dependent ROS
Vasquez-Vivar et al. [31] demonstrated that the binding of doxo-
rubicin to eNOS reductase domain results on O2− generation. The
one-electron reduction by eNOS forms the doxorubicin semiquinone
radical, which reduces oxygen to generate O2−. The importance of
the reductase domain (and not of the oxygenase domain) of eNOS in-
volved in doxorubicin reduction is stressed by the observation that
this reaction is not dependent on Ca2+, is not inhibited by L-NAME,
and is attenuated by diphenyliodonium (NADPH inhibitor). They
also found that at low doxorubicin concentrations, eNOS is the focus
of doxorubicin reduction. The interaction between drug and enzyme
implies that, at increasing doxorubicin concentrations, eNOS will be
transformed from a nitric oxide (NO) to a superoxide generator.
Therefore, it is possible that eNOS inhibition will have far-reaching
consequences in terms of cardiotoxicity. Furthermore, doxorubicin-
induced apoptosis is linked to the redox activation of doxorubicin
by eNOS. Kalivendi et al. [32] demonstrated that doxorubicin treat-
ment causes an increase in eNOS transcription and protein activity
in bovine aortic endothelial cells and pre-treatment with antisense
eNOS mRNA causes a decrease in doxorubicin-induced apoptosis.
Uncoupling of eNOS is already known to be a major contributor to
pressure-overload induced heart failure, [33] and there is some evi-
dence that eNOS-dependent ROS formation also does have a role in
doxorubicin-induced myocardial dysfunction. Indeed, Neilan et al.
[34] demonstrated that genetic disruption of eNOS transcription pro-
tects against the doxorubicin-induced cardiac dysfunction, injury and
mortality via a mechanism that does not require induction of cardio-
protective genes such as COX-2, HO-1, Bcl-xL, and GATA-4. In addi-
tion, they demonstrated that cardiomyocyte-speciﬁc overexpression
of eNOS exacerbates the pathological response to doxorubicin in the
heart [34]. Furthermore, doxorubicin-induced levels of cardiac ROS syn-
thesiswere greatest in eNOS-transgenicmice and least in knockoutmice
[34]. In human studies, endothelium-dependent and -independent
vasodilation was signiﬁcantly attenuated within 30 min of doxorubicin
administration and was accompanied by a signiﬁcant decrease in
serum nitrate levels. These human results are consistent with dysfunc-
tional eNOS activity after doxorubicin administration, especially in
vascular beds [35].The role of inducible nitric oxide synthase (iNOS) in the pathogen-
esis of doxorubicin-induced cardiac dysfunction has been more con-
troversial. Deﬁciency of iNOS has been reported both to enhance
and protect against [36] doxorubicin-induced cardiac toxicity [22].
Neilan et al. [34] did not detect an increase in iNOS mRNA levels in
an acute model of doxorubicin cardiotoxicity, although this ﬁnding
appears to depend on the model, as other papers have shown that
iNOS mRNA levels increase in the presence of doxorubicin [36]. It
appears as though the cardioprotective effects of iNOS are due to
the generation of NO, while the cardiotoxic effects are due to the in-
duction of peroxynitrites that are generated when NO reacts with
O2−. Furthermore, peroxynitrites are known to damage DNA, activat-
ing Poly (ADP-ribose) polymerase, leading to an energetic imbalance
and eventual cell death [36].
The role of the third isoform, neuronal nitric oxide synthase
(nNOS), in doxorubicin-induced cardiomyopathy is less understood.
This isoform can also catalyze one-electron reduction of doxorubicin
and the ﬂavin domain is suggested to have an important role in this
reduction [37]. However, the role of nNOS in doxorubicin induced
cardiotoxicity has been minimized because there are no changes in
myocardial mRNA-expression of nNOS after doxorubicin administra-
tion [38]. In conclusion, from three NOS isoforms, eNOS is the most
important player in doxorubicin-induced cardiomyopathy. Deteriora-
tion in the myocardium due to doxorubicin is attenuated in eNOS KO
mice or following eNOS inhibition, establishing the signiﬁcant role of
eNOS in doxorubicin-induced ROS generation.
2.1.3. NAD(P)H-dependent ROS
Recently, Deng et al. [39] demonstrated that doxorubicin and
NAD(P)H can produce O2− in the absence of any enzymatic activity, al-
though this is a minor source of O2− radicals at best. However, they
also showed that gp91phox (the catalytic domain) knockout mice
were resistant to cardiotoxicity from chronic doxorubicin treatment,
unlike wild-type mice [39]. The importance of the NAD(P)H complex
in the development of doxorubicin induced cardiomyopathy has re-
cently been conﬁrmed pharmacologically in vitro using NAD(P)H in-
hibitors on cultured cell lines and in experiments where inhibitors
of NAD(P)H activity were found to enhance cell survival [40].
Understanding a patient's genetic susceptibility to doxorubicin is
one factor to consider. NAD(P)H is such a large polypeptide complex,
some researchers have theorized that single-nucleotide polymor-
phisms (SNP) in any one of the subunits might make the NAD(P)H
complex more vulnerable to doxorubicin. Wojnowski et al. [41]
were able to correlate the development of doxorubicin-induced car-
diotoxicity with polymorphisms of the NAD(P)H oxidase complex in
non-Hodgkin lymphoma patients. Chronic doxorubicin-induced car-
diotoxicity was associated with an SNP variant of the NAD(P)H oxi-
dase subunit NCF4, which is responsible for down regulation of the
NAD(P)H complex, while acute cardiotoxicity was associated with
SNPs in the p22phox and Rac2 subunits [41]. Therefore, these genetic
polymorphisms in NAD(P)H oxidase might be used as a screening
tool in the future to detect individual patients at a higher risk of
developing doxorubicin-induced cardiotoxicity. Yet polymorphisms
in many other genes may be important in susceptibility. For example,
Blanco et al. demonstrated a correlation between the development of
doxorubicin cardiomyopathy and the CBR3 V244M, variant of the
carbonyl reductase domain, an enzyme involved in doxorubicin's
metabolism [42].
2.1.4. Fe–DOX complex
Doxorubicin–iron complexes have been known since 1980, when
the ﬁrst studies demonstrated that doxorubicin had a strong afﬁnity
for iron [43], and that the iron complex could cause lipid peroxidation
through its interactions with the negatively-charged membranes
[44]. Doxorubicin reduction in the presence of free iron also sets
up a cycle for free radical generation (redox recycling) and the
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proteins, compounding the damages to the cell [45] (Fig. 1). However,
the free iron content of most cells is very low including cardiomyo-
cytes. In physiological conditions, there would not be enough free
iron to couple with doxorubicin to the extent necessary to cause
cardiomyopathy [23]. More recent studies have suggested that the ef-
fects of doxorubicin on iron metabolism are not mediated by doxoru-
bicin–iron interactions, but rather via the proteins that sequester and
bind intracellular iron. One such mechanism involves the doxorubici-
nol metabolite forming complexes with the Fe–S group the cytoplas-
mic aconitase/IRP-1 (iron regulatory protein), thereby enhancing the
stability of transferrin mRNA and preventing translation of iron
sequestration proteins [46]. The subsequent decrease in IRP-1 leads
to an increase in free iron, which could perpetuate the cycle of free
radical generation. Interference with iron sequestration therefore
remains a critical component of doxorubicin-induced cardiotoxicity.
Miranda et al. [47] observed increased susceptibility to doxorubicin-
induced cardiotoxicity in mice depleted of the iron regulatory gene
HFE. In humans, this defective gene is responsible for hereditary
hemochromatosis. Feeding iron-rich chow for 10 to 14 weeks to rats
also resulted in a profound increase in doxorubicin-induced cardio-
toxicity [48]. Both of these studies emphasize the critical role of iron
in the pathogenesis of doxorubicin-induced cardiotoxicity.
There is a wide variability in body iron stores in patients undergoing
cancer chemotherapy due to abnormal blood losses, blood transfusions,
iron supplementation, and nutritional status in these patients. Adult
and pediatric patients undergoing treatment for leukemia and other
malignancies can develop a signiﬁcant level of iron overload during,
and as a result of, chemotherapy and bone marrow transplantation
[49]. If clinical studies conﬁrm the strategic role of iron as an indepen-
dent variable in the pathogenesis of doxorubicin-induced cardiotoxi-
city, the simple and relatively inexpensive screening tests for total
body iron stores and presence of HFEmutation may appear useful.
Regardless of the source, an excess of ROS in the myocardium is
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Fig. 1. Molecular transformations of doxorubicin. Doxorubicin can be reduced to a semiquin
transformation to a C7 free radical, which can interact with molecular oxygen, as well as othe
or FAD/FMN as their electron donors, respectively; NADPH supplies two electrons and FAD/F
can “steal” the electrons away from the normal reactions of generating HB2BOB2B and NO. O
iron, thereby reducing the reactants for molecular oxygen.enzymatic defenses, ROS can also alter gene expression through
their interactions with regulatory proteins. ROS can affect the func-
tion of membrane-bound proteins such as the G-proteins, via lipid
peroxidation. ROS can alter a protein's tertiary structure by oxidizing
S\S bonds. Perhaps, most critically for the myocardium, ROS can in-
duce the release of Ca2+ ions [50].
In spite of the many studies pointing to the role of oxidative stress
in causing cardiomyopathy, it must be noted that, thus far, the admin-
istration of simple antioxidants such as vitamin E do not seem to have
much of a cardioprotective effect against doxorubicin [51]. The
reasons for this are still unclear, but it is becoming apparent that
modifying the cellular response to ROS may be more effective than
trying to eliminate them. Although it is clear that oxidative stress is
an instigator for the development of doxorubicin induced cardiomy-
opathy, the effects of doxorubicin on other cellular events in the myo-
cardium may also play a role in the development of cardiomyopathy,
and contribute to the differences in how individuals respond to
chemotherapy.
2.2. Apoptosis
It is generally accepted that the oxidative stress evoked by doxorubi-
cin activates apoptotic signaling leading to cardiomyocyte apoptosis
[52], and that both the extrinsic and intrinsic apoptotic-pathways are
involved [24,53]. An overview of all apoptotic pathways involved in
doxorubicin-induced cardiotoxicity is given in Fig. 2. It has also become
apparent that doxorubicin can induce apoptosis viamechanisms that do
not directly involve ROS production and oxidative stress, although this
point is complicated by the fact that apoptosis itself also generates
free radicals. An example of the difﬁculties in disentangling oxidative
stress from apoptosis can be found in studies examining the interac-
tions of heat-shock factor 1 (HSF-1), heat-shock protein 25 (Hsp 25),
and p53. In a doxorubicin model, oxidative stress activates HSF-1,
which acts to produce more Hsp25, which stabilizes p53 and increases













one (not depicted) by NADPH oxidase or eNOS. This semiquinone undergoes a further
r intracellular molecules, most notably lipids. NADPH oxidase and eNOS oxidize NADPH
MN can each supply one electron. Because doxorubicin is a potent electron acceptor, it
ne of the mechanisms through which dexrazoxane is believed to act is by chelating free
Fig. 2. Interaction between doxorubicin with the various apoptotic pathways in the cardiomyocyte. The left side of the ﬁgure shows how doxorubicin begins to generate ROS and the
dissociation of the eNOS into monomers. Doxorubicin also enters the mitochondria, causing the release of cytochrome C oxidase, and also prolongs the opening time of calcium
channels in the sarcoplasmic reticulum, which activates calcineurin. Akt phosphorylation inhibits Bad activation and is one of the main anti-apoptotic pathways. Oxidative stress
activates HSF-1 and produces more Hsp25, which increases the pro-apoptotic proteins. Dox: doxorubicin, Doxol: doxorubicinol, Doxq: doxorubicin semiquinone, ROS: reactive
oxygen species, SE: sarcoplasmic reticulum, HSF: heat-shock factor, Hsp: heat-shock protein, CytC: cytochrome C, and Casp3: caspase 3.
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cesses. These proteins are well-established as molecular chaperones,
acting to stabilize their client proteins involved in anti-apoptotic
signaling by preventing their dephosphorylation, ubiquitination,
and degradation [55]. Liu et al. [53] demonstrated that overexpression
of Hsp27, known for its cardioprotective effect against ischemia/
reperfusion injury, also prevents doxorubicin-induced apoptosis and
myocardial dysfunction, due to the protective role of Hsp27 in the reg-
ulation of oxidative stress responses andmaintenance of mitochondrial
function. Overexpression of Hsp10 and Hsp60 likewise results in
increased post-translational modiﬁcation of Bcl-2 proteins, shifting
the balance toward anti-apoptotic signaling, possibly through their
effects as molecular chaperones [55].
Hsp20 enhances the maintenance of Akt phosphorylation, one of
the main cell survival pathways. [56]. In addition, some heat shock
proteins can be secreted into the extracellular space and into the
bloodstream, where they can act as ligands for toll-like receptors
(TLRs). It is likely that they act as ligands for other receptors as
well, but, as of this writing, the most information is available about
TLRs. It has been shown that signaling of Hsp60 can be blocked by an-
tibodies to these peptides, as well as by TLR-2 antagonists [57],
whereas Hsp70 interacts with TLR-4 [58]. Thus far, the roles of TLR-
2 and TLR-4 in doxorubicin-induced cardiomyopathy have been
partially established. TLR-2-mediated signaling through the pro-
inﬂammatory nuclear-factor κB (NFκB) pathway is involved in cyto-
kine production, apoptosis, and cardiac dysfunction after doxorubicin
treatment in vivo, and the abolition of the receptor in knock-out micepreserves cardiac function and prevents apoptosis [59]. TLR-4 has
likewise been shown to act through the NFκB pathway; knockout
mice demonstrate improved cardiac function after doxorubicin
administration over their wild-type counterparts [60]. Although this
pathway appears to be relatively speciﬁc for doxorubicin-induced
apoptosis in many cells, it is not speciﬁc for the myocardium. For
example, the activation of NFκB by doxorubicin has also been demon-
strated in endothelial cells and the kidney [61,62]. Moreover, the
activation of NFκB signaling is not speciﬁc to TLRs, and the modulation
of the pathway initiates the transcription and translation of many
proteins, including inﬂammatory cytokines, which might also be in-
volved in apoptosis.
Caspase activity can also be inﬂuenced by doxorubicin. It was
demonstrated that caspase-3 activation and therefore apoptosis is as-
sociated with doxorubicin administration in vivo [63], but the results
were not duplicated in isolated cardiomyocytes [64]. The results seem
to be system-dependent, or require input frommulticellular tissue, as
both caspase-dependent and -independent mechanisms of cell
death have been documented [65]. It is difﬁcult to determine whether
or how doxorubicin directly inﬂuences caspase activity, as many
pathways can contribute to the activation of caspase-dependent
apoptosis. The administration of the NO donor S-nitrosyl-N-acetyl-
penicillamine (SNAP) produces an anti-apoptotic effect by suppres-
sion of caspase activity via S-nitrosylation in cardiomyocytes treated
with doxorubicin [66]. Blocking volume-sensitive chloride channels
has also been shown to prevent caspase-3 dependent apoptosis in
doxorubicin toxicity [67].
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Doxorubicin-induced cardiotoxicity is also accompanied by an in-
crease in intracellular calcium levels. Dysregulation of intracellular cal-
cium concentrations is both a result and a cause of ROS-generation.
Doxorubicin-mediated ROS generation and apoptosis can be inhibited
by using a Ca2+ chelator [68]. The ROS and H2O2 generated through
mechanisms described above alter normal calcium homeostasis in a
variety of muscle cell types via disruption of normal sarcoplasmic
reticulum function. This is accomplished by inhibiting the Ca2+ ATPase
pump e.g. by reducing the expression-levels of SERCA2a mRNA result-
ing in impaired Ca2+handling [69] and/or by directly activating the rya-
nodine calcium-release channels themselves. Doxorubicin has been
shown to induce the release of calcium from the sarcoplasmic reticulum
by increasing the probability that the channel adopts the open state
[70]. The work of Saeki et al. [71] suggests that the ryanodine channel
has several sites for binding doxorubicin, and that the binding occurs
regardless of whether the channel is open or closed. Doxorubicin has
also been shown to inhibit the sodium–calcium exchanger channel
in the sarcolemma [72], as well as increase the activity of the L-type
calcium channel [73]. In in vitro studies in skeletal muscle cells, H2O2
can modify key thiol groups on the ryanodine Ca2+-release channels
in the sarcoplasmic reticulum [74]. Taken together, this suggests
that calcium dysregulation has a major role in the pathogenesis of
doxorubicin-induced cardiomyopathy.
Like other caspases, caspase-12 also activates apoptotic pathways,
but its activation is speciﬁc to signals of distress from the sarcoplasmic
reticulum, namely calpain dysregulation [75]. Calpains are calcium-
dependent proteases that are activated by calcium; because much of
the intracellular calcium in the cardiomyocyte is contained in the sarco-
plasmic reticulum, oxidative stress can result in calcium leakage,
calpain activation, and caspase-12 cleavage. Experimental results in a
ratmodel show that this is one of themechanisms activated by doxoru-
bicin [76]. However, it is still uncertain how large the role of this system
is in doxorubicin-mediated cardiotoxicity. Furthermore, doxorubicin
cardiomyopathy is associated with myoﬁbrillar deterioration [77],
which may also be a consequence of calpain activation [78]. Calpains
are known to degrade titin, one of the largest proteins and a key compo-
nent of the cardiac sarcomeres. Inhibition, or perhaps more accurately,
prevention of calpain activity could helpmaintain these critical contrac-
tile structures, supported by the work of Lim et al. [78] where calpain
inhibition preserved cardiac function after doxorubicin exposure.
In addition to the direct effects of excessive calcium, doxorubicin en-
hances the sensitivity of the mitochondria to intracellular calcium. The
mitochondria of cells isolated from rats treated with doxorubicin have
a decreased ability to retain calcium, exhibiting a calcium-dependent
calcium release that is not seen in mitochondria from rats treated with
saline [79]. Administration of ruthenium red, a non-speciﬁc inhibitor
of Ca2+ uniporter, is cytoprotective in Sprague–Dawley rat cardiomyo-
cytes from an acute doxorubicinmodel [80]. Increase in intracellular cal-
cium is not the only cause of mitochondrial calcium dysregulation, but
doxorubicin does in addition affect mitochondrial calcium transport,
which contributes to the rise in intracellular calcium levels.
2.4. Changes in the high-energy phosphate pool
Impairment of the cardiac energy homeostasis is one of the main
manifestations of doxorubicin-induced mitochondrial impairment
and apoptosis. Mitochondrial damage impairs the ability to generate
adenosine triphosphate (ATP). The depletion of ATP decreases the
afﬁnity of Hsp90 for ErbB2, a cardioprotective protein that is upregu-
lated in rat myocardium after doxorubicin therapy [81]. In conditions
where ATP may be depleted, erbB2 levels will drop, as HSP90 cannot
maintain its chaperone role [82]. Since erbB2 is coupled to various
GPCRs, this transactivation to the pro-survival ERK1/2 pathways is
impaired [83]. This could explain why the cardiotoxicity oftrastuzumab, an anti-ErbB2 antibody used to treat some breast can-
cers, and doxorubicin are synergistic [84]. Decreases in ATP levels can
also arise from the activation of apoptotic pathways and calcium-
dependent proteases, which consume ATP [78]. Energy expenditures to
replace damaged proteins can also be immense, especially if they are as
large as titin, which is degraded by indiscriminately activated calpain,
Therefore, changes in the high-energy phosphate pool appear to come
aboutmostly as a result of the processes described earlier rather than di-
rectly from doxorubicin itself.
Both acute and chronic consequences of doxorubicin administra-
tion include compromised mitochondrial function, as measured by
respiration and reduced generation of high-energy phosphates with
lowered ratios of phosphocreatine-to-creatine (PCr/Cr), PCr-to-ATP
(PCr/ATP), and ATP-to-ADP (ATP/ADP) [85–87]. Tokarska-Schlattner
et al. [85] demonstrated in a Langendorff rat-model that acute cardiac
dysfunction caused by clinically relevant concentrations of doxorubi-
cin may impair energy signaling via the energy sensor AMP-activated
protein kinase (AMPK),which is consistent with a fast inhibition of
fatty acid oxidation [88] and impaired mitochondrial function.
Creatine kinase (CK) acts as a modulator of the energy reservoir by
converting creatine to phospho-creatine, using ATP as a substrate.
This system is not notably affected in acute doxorubicin-induced
cardiotoxicity, as the ATP/ADP ratio remains fairly constant [89].
However, CK is vulnerable to radical-mediated molecular damage,
known to accumulate over time, inactivating CK isoenzymes to further
impair the function of the sarcomeric mitochondrial CK-isoenzyme
[90,91]. In a mouse-model of doxorubicin-induced cardiomyopathy,
Mihm et al. [91] found signiﬁcant inactivation of myoﬁbril CK (MM-
CK), which is a vulnerable target unique to doxorubicin-induced peroxy-
nitrite generation. Oxidative damage to CK can also be enhanced by the
presence of ferrous iron [90], which is another consequence of doxorubi-
cin administration.
2.5. Endothelin-1
Endothelin-1 (ET-1) signaling increases cell survival signaling in car-
diomyocytes, which explain its upregulation in heart failure [92]. ET-1
expression and the expression of its receptors are increased in the
myocardium of rats with congestive heart failure [93], in patients with
idiopathic dilated cardiomyopathy [94], and in patients treated with
doxorubicin [95]. However, the beneﬁt of activating pro-survival path-
ways is counteracted by the vasoconstrictive effects of endothelin-1
on the vasculature [96]. In the vasculature, the activity of ET-1 is bal-
anced by the effects of NO [97], but in patients treatedwith doxorubicin,
NO production is impaired.
Recently, Bien et al. [98] demonstrated in mice that pre-treatment
with the combined ETA/Endothelin B (ETB) antagonist bosentan
signiﬁcantly reduced doxorubicin-induced cardiotoxicity with pres-
ervation of myocardial contractility. This beneﬁcial effect was associ-
ated with reduced TNF-α and BAX expression, lipid peroxidation and
increased expression of GATA-4 [98]. Similar results were observed
with the ETA/ETB antagonist LU420627, but not the selective ETB
antagonist LU135252 in animals over-expressing endothelin-1 in
cardiomyocytes [99]. Molecular studies indicate that ETB agonists
can increase NO production. These data support a substantial role of
endothelin-1 signaling through the ETA receptor as a mediator of
doxorubicin cardiotoxicity. However, no corresponding clinical data
in patients with doxorubicin-induced heart failure are available at
the moment to conﬁrm these experimental data.
2.6. Extracellular matrix remodeling
Both cellular and extracellular factors do have an important role in
the complex process of myocardial remodeling. Signiﬁcant alterations
in the structure and composition of the extracellular matrix contrib-
ute to the development of heart failure [100]. Doxorubicin inhibits
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nase 1 (MMP-1) in tumor cells, decreasing tumor cell mobility. It has
since been shown that doxorubicin has the opposite effect on the
heart, enhancing production of matrix metalloproteinases-2 and -9
(MMP-2, MMP-9) [101,102]. This is believed to contribute to cardiomy-
opathy by weakening the collagenous matrix against which the cardio-
myocytes work and contributing to pathological remodeling. Both
MMP-2 and MMP-9 activities are enhanced by doxorubicin-induced
ROS generation, although Spallarosa et al. [102] show thatMMP-2 levels
depend onNADPHoxidase levels. Tissue-inhibitor ofmetalloproteinase-
3 (TIMP, the family which includes MMP-2 andMMP-9) also decreased
after doxorubicin administration [103], which is consistent with the
apparent increase in MMP-2 and MMP-9 activity in earlier studies.
2.7. Other mechanisms
Other novel cytotoxic mechanisms have been explored and while
they are not very well characterized, research suggests that they are
also not trivial.
2.7.1. COX-2 inhibitors
Co-administration of diclofenac sodium, a cyclooxygenase-2 (COX-2)
inhibitor, to rats receiving doxorubicin aggravates doxorubicin-induced
myocardial apoptosis by accompanying increases in serum lactate dehy-
drogenase, increases in cardiac thiobarbituric acid reactive substances
(lipid peroxidation indicator) and catalase expression, possibly to coun-
teract the damage caused by oxidative stress [104]. Induction of COX-2 is
believed to be cardioprotective through the induction of molecules such
as prostacyclins [105]. The induction of COX-2 activity occurs concomi-
tantly with doxorubicin administration in a rat model, and administra-
tion of PGI2, a downstream product of COX-2 activity, could prevent
injury to the myocardium. Administration of a COX-2 inhibitor prevents
the enzyme from generating prostacyclins, removing a cardioprotective
mechanism [105].
2.7.2. Neuregulin signaling
Neuregulin is a small paracrine peptide that signals through the
ErbB family of tyrosine kinase receptors, activating cell survival path-
ways. The results of a very recent study by Horie et al. [106] demon-
strated that acute doxorubicin cardiotoxicity is associated with an
increase in miRNA-146a, speciﬁc for downregulation of the ErbB4
protein, and that doxorubicin-induced increases in miR-146a levels
are dose-dependent. The downregulation of ErbB4 is accompanied
by increased levels of apoptosis, as indicated by decreased Akt signal-
ing and increased caspase-3 cleavage. Interestingly, the authors do
not detect a change in ErbB2 mRNA or protein levels, after acute
doxorubicin administration. This is in contrast to what is seen in a
chronic rat model, where doxorubicin exposure induces upregulation
of ErbB2 protein, not mRNA, most likely through the upregulation of
HSP90, erbB2's chaperone [81]. ErbB4 levels are unchanged in this
same model.
2.7.3. Ceramide accumulation
It is known that ceramide accumulation in the cell membrane trig-
gers apoptosis via caspase-3 activation, although the exact mecha-
nism with respect to how this occurs remains unclear. Ceramide has
been implicated in two separate pathways relating to doxorubicin-
induced cardiomyopathy, one involving mitochondrial L-carnitine.
When L-carnitine was applied to isolated adult rat cardiomyocytes
in the presence of clinically relevant doxorubicin concentrations,
ceramide levels returned to nearly baseline levels while sphingomy-
elin, one of the precursors of ceramide, did not decrease [107]. This
was correlated with L-carnitine inhibition of sphingomyelinase and
prevented doxorubicin-induced apoptosis of cardiac myocytes [107].
The other pathway involves the volume-sensitive chloride ion chan-
nel [I(Cl, vol)]. Electrophysiological measurements on isolated cardiacmyocytes show that doxorubicin administration (1 μM, clinically rel-
evant) is accompanied by a current, that is characterized as I(Cl, vol)
based on external chloride sensitivity, and occurs simultaneously
with cell shrinkage and volume decrease, one of the hallmarks of ap-
optosis [108].
2.7.4. Cannabinoid signaling
In a rat model of doxorubicin cardiotoxicity, administration of
cannabinoid-1 (CB1) receptor antagonists improved the degree of
cardiac dysfunction [109]. The same group showed that administra-
tion of the agonist anandamide or HU210 activates apoptotic path-
ways and ampliﬁes ROS and reactive nitrogen species production
that is already induced by doxorubicin therefore compounding the
damage [110]. It should be noted that one study purports to refute
these data and suggests that anandamide preserves cardiac function
in doxorubicin cardiotoxicity, measured by pressure measurements
and fractional shortening [111].
3. Symptoms and diagnostic tools
Doxorubicin-induced cardiotoxicity may be divided into acute,
subacute and late forms. Acute cardiotoxicity starts within 24 h of
the infusion and includes ECG abnormalities such as atypical ST-T
changes, reduced QRS voltages, sinus tachycardia, premature supra-
ventricular and ventricular complexes, QT interval prolongation,
and, rarely, acute myocardial ischemia. In spite of this, the prognosis
is fairly good at this stage. These electrocardiographic changes are
usually associated with few symptoms, but may also be completely
asymptomatic, and usually resolve spontaneously within several
hours or weeks after the completion of chemotherapy in most pa-
tients. The golden standard for detection of acute doxorubicin-
induced cardiotoxicity is endomyocardial biopsy of the right ventricle
because of its high sensitivity and speciﬁcity [112]. Endomyocardial
tissue from the right ventricle will show typical histopathological
changes, including vacuolization of the cytoplasm, while by electron
microscopy, the common ﬁndings are loss of myoﬁbrils and disten-
tion of the sarcoplasmic reticulum and T-tubules. The biopsy is scored
and uses a scale where a 1 (b5% of cells show typical changes), 1.5 (5-
15%), 2 (16-25%), 2.5 (26–35%) and 3 (>35%) grade scale [113]. A bi-
opsy score of 2.5 or higher is a strong indicator that doxorubicin ther-
apy should be terminated [113]. However, endomyocardial biopsy is
rarely used, because the procedure is considered high risk, although
it is not. Acute doxorubicin-induced cardiotoxicity occurs in up to
40% of the patient population. Tests for acute cardiomyopathy include
monitoring ECG abnormalities, assessing adrenergic denervation and
energy metabolism through radionuclide scanning, and using cardiac
biomarkers such as cardiac troponin-T to assess cellular injury [114].
Sub-acute cardiotoxicity is rather rare, appears several weeks or
months (as late as 30 months) after the last dose of anthracycline
and its most frequent manifestation is myo/pericarditis [115]. Micro-
scopically, severe interstitial myocardial edema without a cellular
inﬁltrate is seen. The chronic form may not become evident until as
many as 4 to 20 years after the last administration of doxorubicin,
and is associated with progressive myocardial dysfunction. It has
been demonstrated that the mortality rate in these patients is 50%
after ﬁve years [114]. Sporadic, spontaneous reversal of severe LV
dysfunction has been reported, usually after an acute-onset of the
symptoms [116,117].
Early detection ofmyocardial damagemight enable implementation
of preventive measures that could reduce the likelihood of further
development to ventricular decompensation, but as of this writing,
the best preventative measure is to limit doxorubicin chemotherapy.
Serial echocardiographic monitoring is generally used for cardio-
toxicity detection [12]. Evaluation of left ventricular systolic function
using ejection fraction, or fractional shortening by echocardiography,
as well as, nuclear ventriculography, will detect development of
1220 Y. Octavia et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 1213–1225cardiomyopathy. However, these are insensitive and still inaccurate
markers of early doxorubicin injury [118,119], as the guidelines for
terminating doxorubicin are based on a preset decrease in left ven-
tricular ejection fraction [120]. Several other radionuclide-based
tests are currently being developed; one of them, technetium99m-
labeled annexin V seems the most promising. In early animal tests,
the increase in Tc99 uptake correlates well with the degree of
doxorubicin-induced cardiomyopathy [120] and the method is sensi-
tive enough to detect dose-dependent doxorubicin-mediated cell
death in a rat model, even before echocardiography detected systolic
dysfunction [121]. However, no clinical validation of this latter diag-
nostic tool is yet available.
Furthermore, in a rodent model of doxorubicin-induced cardio-
myopathy, it has been demonstrated that 2-dimensional radial strain
echocardiography, a novel method of assessing myocardial function
that is based on measuring myocardial deformation using speckle
tracking from B mode images, can be useful in the early detection
of doxorubicin cardiac injury. Strain is a measure of myocardial de-
formation, which is an intrinsic mechanical property. The reduction
in radial strain is associated with the degree and the onset of histo-
logic indices of myocardial injury. In this way, myocardial dysfunc-
tion can be detected using radial strain earlier than with standard
assessment of ventricular function [122]. Low-dose dobutamine
stress echocardiography, which detects myocardial contractile re-
serve, (5–10 μg/kg/min) can also be used in the clinic as a safe and
sensitive indicator of diminished myocardial function [123,124].
Other indices of diastolic function such as isovolumic relaxation pe-
riod, early peak mitral ﬂow velocity and the ratio of early/atrial mi-
tral peak ﬂow velocity [125,126] were found to be useful in earlier
detection of doxorubicin cardiomyopathy, but their practicalFig. 3. Pharmacologic interventions. The known activities of the newer targets and the d
adrenergic receptor and angiotensin II receptor is cardioprotective. Carvedilol enhances tr
of calcium. Resveratrol and carvedilol (and, presumably, other β-blockers as well) prevent d
to inhibit signaling through small G-proteins. EPO: erythropoietin, ACEi: angiotensin-conve
nitric oxide, O2−: superoxide, and CYTc: cytochrome C.applicability in the clinical setting is limited due to considerable indi-
vidual variability.
Since doxorubicin disrupts cardiac myocyte cell membranes, bio-
markers can be used to assay for the presence and extent of myocyte
injury. Lipshultz et al. [127] demonstrated the utility of cardiac tropo-
nin T (cTnT) as a possible quantiﬁer for acute doxorubicin-induced
myocardial injury. Other potential markers include plasma levels of
circulating natriuretic peptides, such as atrial-type and brain-type
natriuretic peptides (ANP and BNP, respectively), which are elevated
in left ventricular dysfunction and heart failure. Levels of these pro-
teins were signiﬁcantly elevated in a subgroup of patients treated
with doxorubicin who had cardiac dysfunction, compared with
healthy controls or patients with normal cardiac function [128,129].
Cardiac biomarkers can be good indicators of doxorubicin-induced
myocardial injury and can provide useful diagnostic information,
especially when used in combination with assessment of left ventric-
ular function.
4. Therapeutic and preventive possibilities
The challenge for the future is to design protocols that are cardiopro-
tective for both the short-term and long-term effects of doxorubicin,
preferably without long-term administration and without hindering
the antitumor activity of the drug. An overview of the possible thera-
peutic strategies to reduce doxorubicin-induced cardiotoxicity is
shown in Fig. 3.
The most effective tool to prevent doxorubicin-induced cardio-
toxicity is modulating the dosage. It has been reported in several
studies, that a lower weekly dosage, or even continuous infusion,
will permit adequate solid tumor suppression while limiting initialrugs that have been mentioned are depicted here. Receptor signaling through the β-
anscription of calcium-channel mRNA, while resveratrol inhibits the improper release
issociation of the eNOS dimer. Erythropoietin directly inhibits apoptosis. Statins appear
rting enzyme inhibitors, AT: angiotensin, eNOS: endothelial nitric oxide synthase, NO:
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cy of doxorubicin depends not only upon the concentration, but also
on the amount of time the drug is present in the body.
Dexrazoxane is the most studied cardioprotective adjuvant for
doxorubicin chemotherapy. Although it was initially introduced as
an antineoplastic agent in its own right, due to its ability to interfere
with topoisomerase II activity, several studies have demonstrated
possible cardioprotective properties, partially due to the hydrolyzed
metabolite that chelates free iron [132,133]. In addition, it has also
been shown to prevent depletion of mitochondrial DNA in a chronic
rat-model of doxorubicin-induced cardiotoxicity [134].
The clinical trials examining the role of dexrazoxane as a cardio-
protectant by Lipshultz et al. [127] demonstrated in doxorubicin-
treated children with acute lymphoblastic leukemia that dexrazoxane
therapy reduced myocardial injury, as indicated by decreased serum
troponin T. Moreover, in a relatively large population of children
with acute lymphoblastic leukemia (n=205), dexrazoxane was not
associated with an increased risk of a second malignant event [135],
as suggested earlier [136] and is therefore recommended to be ad-
ministered with doxorubicin-containing pediatric regimens [135].
The clinical practice guidelines of 2008 suggests using a 10:1 ratio
of dexrazoxane-to-anthracycline, administered 15–30 min prior to
doxorubicin administration, but it should be mentioned that the opti-
mal dose of dexrazoxane has not been empirically established [137].
The American Society of Clinical Oncology does not endorse the rou-
tine use of dexrazoxane with anthracycline chemotherapy, although
they do note exceptions for situations where the cumulative dose of
anthracyclines approaches or exceeds 300 mg/m2 [137].
Another cardioprotective agent is monoHER, the main constituents
of ﬂavonoids Venoruton (O-(β-hydroxyethyl)-rutosides) [138]. Pre-
treatmentwithmonoHER protects against doxorubicin-induced cardio-
toxicity in both an in vivo and ex vivo mouse model of chronic
doxorubicin-induced cardiotoxicity [139,140]. In vitro and in vivo
experiments have shown that monoHER did not interfere with the
antitumor effect of doxorubicin [141]. High doses of monoHER
(>1500 mg/m2) are indicated for potentiating the effect of antitumor
and low doses for cardioprotection effect [142]. Further clinical investi-
gations are needed to assert monoHER's dose–response characteristics.
Beta-adrenergic antagonists and angiotensin-converting enzyme
(ACE) inhibitors are the keystrokes of standard heart failure therapy.
Kalay et al. [143] demonstrated that left ventricle diameters remained
constant and diastolic function was better preserved after doxorubicin-
treatment in patients receiving carvedilol, compared with placebo.
Georgakopoulos et al. [144], demonstrated that metoprolol, a β-blocker
without antioxidative properties, failed to give cardioprotection in
lymphoma-treated doxorubicin patients. Early additions of β-blockers
along with angiotensin-converting enzyme inhibitors have also been
demonstrated to improve myocardial contractility in doxorubicin-
induced cardiotoxicity, but the exact mechanism is still poorly under-
stood [145]. In patients with congestive heart failure after epirubicin
treatment, the administration of ACE inhibitors (enalapril or ramipril)
restored systolic function after the relief from digoxin or administration
of a diuretic is stopped [146]. This beneﬁt was independently observed
with both zofenepril and captopril [147–149]. Furthermore, the degree
of improvement is the same whether a receptor antagonist or an
ACE-inhibitor is used [150]. These indicate that some aspect of angioten-
sin signaling could be involved in alleviating doxorubicin-induced
cardiomyopathy.
Erythropoietin (EPO) is commonly used for treating anemia in
patients who have undergone chemotherapy by restoring red blood
cell production. EPO has the potential to act as a cardioprotective
agent against doxorubicin-induced apoptosis and cardiomyopathy, es-
pecially when administered prophylactically [151]. Clinical trials with
epoetin alfa in patients with advanced-stage Hodgkin's lymphoma
showed an improvement in doxorubicin-induced anemia and no differ-
ence between placebo and treatment groups in cancer treatmentoutcome, which means the combination does not affect the cell-killing
ability from doxorubicin [152].
Preventive administration of sildenaﬁl, a phosphodiesterase 5
inhibitor, can attenuate cardiomyocyte apoptosis, preserve the mito-
chondrial membrane potential, maintain myoﬁbrillar integrity, pre-
vent ST-interval prolongation, and left ventricular dysfunction in a
mouse model of doxorubicin-induced chronic cardiotoxicity [153].
These effects are NOS-dependent and establish the signiﬁcant role
of mitochondrial KATP channel opening in sildenaﬁl induced cardio-
protection. The authors hypothesize that pretreatment with sildenaﬁl
helps to maintain mitochondrial integrity by augmenting cellular
mechanisms mediated by NO/cyclic GMP [153]. Other studies demon-
strated the combination between sildenaﬁl and doxorubicin in-
creased cell-killing effect of doxorubicin in cancer cells [154] and
improved cardiac function [155]. These effects could be due to the
combination that sildenaﬁl and doxorubicin produce greater amounts
of ROS in cancer cells. On the other hand, this combination produced
less ROS in normal cells [156]. Future clinical studies addressing these
interesting mechanisms are required and worth pursuing.
Tatlidede et al. [157] showed that resveratrol, a broad antioxidant,
pretreatment for two weeks in acute doxorubicin treatment signiﬁ-
cantly decreased ROS generation, improved glutathione, SOD and cat-
alase activity, which subsequently generate better cardiac function. It
stands to reason that pretreating patients with resveratrol can be car-
dioprotective for doxorubicin-induced cardiotoxicity, but so far, no
large clinical trials have been done.
The beneﬁcial effect of cardiac resynchronization therapy (CRT) on
doxorubicin-induced heart failure in patients who are non-responders
to pharmacologic therapy, and meet criteria for resynchronization
device implantation has been observed in a pilot-trial [158]. This
study demonstrated improved left ventricular ejection fraction, reduced
end-diastolic dimensions, reduced heart failure symptoms, and im-
proved function [158]. While the number of patients was very limited,
all were highly responsive to CRT in this study (9 to 24 months). The
long-term sustainability of the observed beneﬁcial response to CRT
remains unknown at the moment.
Lastly, Ward et al. [159] conclude that transplantation is an
acceptable treatment option for pediatric patients with intractable
cardiac failure secondary to anthracycline therapy. They demonstrat-
ed that survival is comparable with ISHLT Registry data for all pediat-
ric heart recipients and that tumor recurrence after transplantation
is rare, even with immunosuppression [159]. Current guidelines
regarding the duration of a cancer-free interval before listing should
be re-examined on an individual basis, with input from the oncologist
and consideration of type of tumor, stage, grade, and response to
initial therapy [159].
5. Conclusion
Doxorubicin-induced cardiomyopathy is an important public
health concern because it may not be detected for many years and re-
mains a life-long threat. This is of particular importance in children
who may survive for decades after successful antineoplastic treat-
ment. There is strong evidence that the surveillance of patients trea-
ted with anthracyclines should be prolonged to more than 10 years
to deﬁne the real impact of anthracyclines on the myocardium, espe-
cially when these patients have received a co-administration of other
agents that may induce cardiac damage such as trastuzumab, pacli-
taxel, etoposide, teniposide, the vinca alkaloids, ﬂuorouracil, cytara-
bine, amsacrine, cladribine, asparaginase, tretinoin and pentostatin.
The search for cardioprotective agents will continue to rely on
increasing our understanding of the mechanisms of doxorubicin-
induced cardiotoxicity and how to counteract them.
The take home messages of this review are that there are some
strategies that will reduce this cardiovascular side effect. First, lower
doses of doxorubicin, continuous infusion, or different formulations
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cin and other cardiotoxic chemotherapeutic agents, such as trastuzu-
mab will aggravate the cardiotoxic effects [161]. Third, in clinical
situation, dexrazoxane can be considered to reduce the cardiotoxicity
in patients who have received a cumulative dose of doxorubicin
>300 mg/m2 [137]. In addition, according to European Society of
Cardiology, the cardiovascular status of cancer patients must be
adequately monitored and when they develop heart failure, the treat-
ments for doxorubicin-induced cardiotoxicity will follow the stan-
dard guideline for heart failure [162]. Currently, no clear guidelines
are available for treating doxorubicin-induced cardiotoxicity in
adults, emphasizing the need to detect doxorubicin-induced cardio-
toxicity as early as possible to limit/prevent subsequent damage.
Despite the predominant role of ROS in doxorubicin-induced
cardiotoxicity, many of the potential protectants do not appear to
affect the production of free radicals at all, but instead seem to alter
the cellular response to ROS. Increasingly, more researchers are
moving away from efforts to minimize or eliminate ROS, and target-
ing the cellular mechanisms that cause apoptosis instead. This shift
in approaching the problem may lead to interesting applications of
older drugs, as well as a more systems biology-oriented approaches
to develop solutions against doxorubicin-induced cardiotoxicity.
Disclosure statement
None declared.
Acknowledgments and ﬁnancial support
The authors would like to thank Judy Lin, Courtney Tribble and Jan
Gielis for excellent technical assistance, careful editing and graphical
assistance. Financial support was obtained from the Dutch Heart
Foundation (NHS project number 30982277) and NWO/ZonMw
(Vidi/Aspasia-funding), both to ALM.
References
[1] Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992;19:
529–42.
[2] Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl
Cardiol 2000;7:53–62.
[3] Lipshultz SE, Lipsitz SR,Mone SM, GoorinAM, Sallan SE, Sanders SP, et al. Female sex
and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for
childhood cancer. N Engl J Med 1995;332:1738–43.
[4] Lanzarini L, Bossi G, Laudisa ML, Klersy C, Arico M. Lack of clinically signiﬁcant
cardiac dysfunction during intermediate dobutamine doses in long-term child-
hood cancer survivors exposed to anthracyclines. Am Heart J 2000;140:315–23.
[5] Sorensen K, Levitt G, Sebag-Monteﬁore D, Bull C, Sullivan I. Cardiac function in
Wilms' tumor survivors. J Clin Oncol 1995;13:1546–56.
[6] Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac
dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993;21:477–9.
[7] Biancaniello T, Meyer RA, Wong KY, Sager C, Kaplan S. Doxorubicin cardiotoxicity
in children. J Pediatr 1980;97:45–50.
[8] Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxo-
rubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse
B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159–65.
[9] Godoy LY, Fukushige J, Igarashi H, Matsuzaki A, Ueda K. Anthracycline-induced
cardiotoxicity in children with malignancies. Acta Paediatr Jpn 1997;39:188–93.
[10] Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac ab-
normalities 15 years and more after adriamycin therapy in 229 childhood survi-
vors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004;91:37–44.
[11] Saltiel E, McGuire W. Doxorubicin (adriamycin) cardiomyopathy. West J Med
1983;139:332–41.
[12] Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med
1998;339:900–5.
[13] Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of
anthracycline-induced clinical heart failure in children: a systematic review.
Ann Oncol 2002;13:503–12.
[14] Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium
are mediated by oxygen free radicals. Life Sci 2001;68:889–901.
[15] Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-
induced cardiotoxicity: overview of studies examining the roles of oxidative
stress and free cellular iron. Pharmacol Rep 2009;61:154–71.[16] Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-
induced cardiotoxicity and its prevention. Mol Genet Metab 2000;71:436–44.
[17] Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart
against reactive oxygen metabolites: alterations produced by doxorubicin. J
Clin Invest 1980;65:128–35.
[18] Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a complex
between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity.
Biochem Pharmacol 1980;29:3003–10.
[19] Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardi-
olipin. Prog Lipid Res 2000;39:257–88.
[20] Kashﬁ K, Israel M, Sweatman TW, Seshadri R, Cook GA. Inhibition of mitochon-
drial carnitine palmitoyltransferases by adriamycin and adriamycin analogues.
Biochem Pharmacol 1990;40:1441–8.
[21] Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J
Physiol 2004;555:1–13.
[22] Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, et al. The
protective roles of nitric oxide and superoxide dismutase in adriamycin-
induced cardiotoxicity. Cardiovasc Res 2006;69:186–97.
[23] Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular
advances and pharmacologic developments in antitumor activity and cardiotoxi-
city. Pharmacol Rev 2004;56:185–229.
[24] Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. Structural
and functional impairment of mitochondria in adriamycin-induced cardiomyop-
athy in mice: suppression of cytochrome c oxidase II gene expression. Biochem
Pharmacol 1999;57:481–9.
[25] Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, Bjork JA, et al.
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
Toxicology 2010;270:92–8.
[26] Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA.
The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents
murine doxorubicin cardiomyopathy. J Clin Invest 2007;117:3730–41.
[27] Piantadosi CA, Carraway MS, Babiker A, Suliman HB. Heme oxygenase-1 regu-
lates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control
of nuclear respiratory factor-1. Circ Res 2008;103:1232–40.
[28] Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, et al. Deregu-
lated manganese superoxide dismutase expression and resistance to oxidative
injury in p53-deﬁcient cells. Cancer Res 2000;60:4654–60.
[29] Kim DS, Kim HR, Woo ER, Kwon DY, Kim MS, Chae SW, et al. Protective effect of
calceolarioside on adriamycin-induced cardiomyocyte toxicity. Eur J Pharmacol
2006;541:24–32.
[30] Xiong Y, Liu X, Lee CP, Chua BH, Ho YS. Attenuation of doxorubicin-induced con-
tractile and mitochondrial dysfunction in mouse heart by cellular glutathione
peroxidase. Free Radic Biol Med 2006;41:46–55.
[31] Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard Jr KA, Kalyanaraman
B. Endothelial nitric oxide synthase-dependent superoxide generation from
adriamycin. Biochemistry 1997;36:11293–7.
[32] Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-induced
apoptosis is associated with increased transcription of endothelial nitric-oxide
synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem 2001;276:
47266–76.
[33] Moens AL, Leyton-Mange JS, NiuX, YangR, Cingolani O, Arkenbout EK, et al. Adverse
ventricular remodeling and exacerbated NOS uncoupling from pressure-overload
in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol 2009;47:576–85.
[34] Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, et al. Disruption of
nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mor-
tality induced by doxorubicin. Circulation 2007;116:506–14.
[35] Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, et al. Rapid-
onset endothelial dysfunction with adriamycin: evidence for a dysfunctional
nitric oxide synthase. Vasc Med 2003;8:101–7.
[36] Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. Role
of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death
in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296:H1466–83.
[37] Fu J, Yamamoto K, Guan ZW, Kimura S, Iyanagi T. Human neuronal nitric oxide
synthase can catalyze one-electron reduction of adriamycin: role of ﬂavin do-
main. Arch Biochem Biophys 2004;427:180–7.
[38] Liu B, Li H, Qu H, Sun B. Nitric oxide synthase expressions in ADR-induced cardio-
myopathy in rats. J Biochem Mol Biol 2006;39:759–65.
[39] Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-
containing NAD(P)H oxidase increases superoxide formation by doxorubicin and
NADPH. Free Radic Biol Med 2007;42:466–73.
[40] Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, Lancel S. NADPH
oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Bio-
chem Biophys Res Commun 2009;388:727–31.
[41] Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al.
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are as-
sociated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754–62.
[42] Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM,
Relling MV, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3
and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who devel-
oped anthracycline-related congestive heart failure after childhood cancer. Can-
cer 2008;112:2789–95.
[43] May PM, Williams GK, Williams DR. Solution chemistry studies of adriamycin–
iron complexes present in vivo. Eur J Cancer 1980;16:1275–6.
[44] Kappus H, Muliawan H, Scheulen ME. In vivo studies on adriamycin-induced
lipid peroxidation and effects of ferrous ions. Dev Toxicol Environ Sci 1980;8:
635–8.
1223Y. Octavia et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 1213–1225[45] Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of
anthracyclines with iron. Mol Pharmacol 2005;68:261–71.
[46] Minotti G, Recalcati S, Mordente A, Liberi G, Calaﬁore AM,Mancuso C, et al. The sec-
ondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron
regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J
1998;12:541–52.
[47] Miranda CJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vali H, et al. Hfe deﬁciency in-
creases susceptibility to cardiotoxicity and exacerbates changes in iron metabo-
lism induced by doxorubicin. Blood 2003;102:2574–80.
[48] Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of
doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol
2007;49:2457–64.
[49] Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia:
manifestations and therapy. Am J Med Sci 2000;319:73–8.
[50] Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular
diseases. J Hypertens 2000;18:655–73.
[51] Bjelogrlic SK, Radic J, Jovic V, Radulovic S. Activity of d,l-alpha-tocopherol
(vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin
with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol 2005;97:311–9.
[52] Nitobe J, Yamaguchi S, Okuyama M, Nozaki N, Sata M, Miyamoto T, et al. Reactive
oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-
mediated apoptosis in cardiac myocytes. Cardiovasc Res 2003;57:119–28.
[53] Liu B, Bai QX, Chen XQ, Gao GX, Gu HT. Effect of curcumin on expression of sur-
vivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo Shi Yan Xue
Ye Xue Za Zhi 2007;15:762–6.
[54] Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, et al. Role of
heat shock factor-1 activation in the doxorubicin-induced heart failure in mice.
Am J Physiol Heart Circ Physiol 2010;298:H1832–41.
[55] Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60
modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxoru-
bicin in cardiac muscle cells. J Mol Cell Cardiol 2003;35:1135–43.
[56] Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P, et al. Heat shock protein 20
interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative
stress and cardiotoxicity. Circ Res 2008;103:1270–9.
[57] Kim SC, Stice JP, Chen L, Jung JS, Gupta S, Wang Y, et al. Extracellular heat shock
protein 60, cardiac myocytes, and apoptosis. Circ Res 2009;105:1186–95.
[58] Rayner K, Chen YX, McNulty M, Simard T, Zhao X, Wells DJ, et al. Extracellular re-
lease of the atheroprotective heat shock protein 27 is mediated by estrogen and
competitively inhibits acLDL binding to scavenger receptor-A. Circ Res
2008;103:133–41.
[59] Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced car-
diac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004;110:
2869–74.
[60] Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, et al. Toll-like
receptor-4 deﬁciency attenuates doxorubicin-induced cardiomyopathy in mice.
Eur J Heart Fail 2008;10:233–43.
[61] Chen C, Jin Y. Effects of oxymatrine on expression of nuclear factor kappa B in
kidneys of rats with adriamycin-induced chronic renal ﬁbrosis. Nan Fang Yi Ke
Da Xue Xue Bao 2007;27:345–8.
[62] Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activa-
tion of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothe-
lial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem
J 2002;367:729–40.
[63] Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, et al. Doxo-
rubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes
in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006;101:151–8.
[64] Youn HJ, Kim HS, Jeon MH, Lee JH, Seo YJ, Lee YJ, et al. Induction of caspase-
independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol
Cell Biochem 2005;270:13–9.
[65] Bruynzeel AM, Abou El Hassan MA, Torun E, Bast A, van der Vijgh WJ, Kruyt FA.
Caspase-dependent and -independent suppression of apoptosis by monoHER in
doxorubicin treated cells. Br J Cancer 2007;96:450–6.
[66] Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial
apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol
2005;38:163–74.
[67] d'Anglemont de Tassigny A, Berdeaux A, Souktani R, Henry P, Ghaleh B. The
volume-sensitive chloride channel inhibitors prevent both contractile dysfunc-
tion and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2.
Eur J Heart Fail 2008;10:39–46.
[68] Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, et al.
Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand
transcription: role of mitochondrial reactive oxygen species and calcium. Bio-
chem J 2005;389:527–39.
[69] Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al. Mecha-
nism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase
gene transcription. Circ Res 2000;86:8–14.
[70] Holmberg SR, Williams AJ. Patterns of interaction between anthraquinone drugs
and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res
1990;67:272–83.
[71] Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Doxorubicin di-
rectly binds to the cardiac-type ryanodine receptor. Life Sci 2002;70:2377–89.
[72] Caroni P, Villani F, Carafoli E. The cardiotoxic antibiotic doxorubicin inhibits the
Na+/Ca2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett 1981;130:184–6.
[73] Keung EC, Toll L, Ellis M, Jensen RA. L-type cardiac calcium channels in doxoru-
bicin cardiomyopathy in rats morphological, biochemical, and functional corre-
lations. J Clin Invest 1991;87:2108–13.[74] Favero TG, Zable AC, Abramson JJ. Hydrogen peroxide stimulates the Ca2+ re-
lease channel from skeletal muscle sarcoplasmic reticulum. J Biol Chem
1995;270:25557–63.
[75] Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 medi-
ates endoplasmic-reticulum-speciﬁc apoptosis and cytotoxicity by amyloid-beta.
Nature 2000;403:98–103.
[76] Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D, et al. Doxorubicin
treatment in vivo activates caspase-12 mediated cardiac apoptosis in both
male and female rats. FEBS Lett 2004;577:483–90.
[77] Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of
anthracycline-induced myoﬁbrillar disarray in rat ventricular myocytes by
neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-
induced cardiotoxicity. Circulation 2002;105:1551–4.
[78] Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, et al.
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardi-
omyocytes. J Biol Chem 2004;279:8290–9.
[79] Solem LE, Heller LJ, Wallace KB. Dose-dependent increase in sensitivity to
calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by
doxorubicin. J Mol Cell Cardiol 1996;28:1023–32.
[80] Chacon E, Ulrich R, Acosta D. A digitized-ﬂuorescence-imaging study of mito-
chondrial Ca2+ increase by doxorubicin in cardiac myocytes. Biochem J
1992;281(Pt 3):871–8.
[81] GabrielsonK, Bedja D, Pin S, Tsao A, Gama L, Yuan B, et al. Heat shock protein 90 and
ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 2007;67:1436–41.
[82] Peng X, Guo X, Borkan SC, Bharti A, Kuramochi Y, Calderwood S, et al. Heat shock
protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in
myocytes. J Biol Chem 2005;280:13148–52.
[83] Negro A, Brar BK, Gu Y, Peterson KL, Vale W, Lee K-F. erbB2 is required for G
protein-coupled receptor signaling in the heart. Proc Natl Acad Sci 2006;103:
15889–93.
[84] Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac
dysfunction on treatment outcomes in women receiving trastuzumab for HER2-
overexpressing metastatic breast cancer. Clin Breast Cancer 2004;5:293–8.
[85] Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC,
Wallimann T, et al. Acute toxicity of doxorubicin on isolated perfused heart: re-
sponse of kinases regulating energy supply. Am J Physiol Heart Circ Physiol
2005;289:H37–47.
[86] Keller AM, Jackson JA, Peshock RM, Rehr RB, Willerson JT, Nunnally RL, et al. Nu-
clear magnetic resonance study of high-energy phosphate stores in models of
adriamycin cardiotoxicity. Magn Reson Med 1986;3:834–43.
[87] Nicolay K, Aue WP, Seelig J, van Echteld CJ, Ruigrok TJ, de Kruijff B. Effects of the
anti-cancer drug adriamycin on the energy metabolism of rat heart as measured
by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity.
Biochim Biophys Acta 1987;929:5–13.
[88] Bordoni A, Biagi P, Hrelia S. The impairment of essential fatty acid metabolism as
a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes. Bio-
chim Biophys Acta 1999;1440:100–6.
[89] Chatham JC, Cousins JP, Glickson JD. The relationship between cardiac function
and metabolism in acute adriamycin-treated perfused rat hearts studied by
31P and 13C NMR spectroscopy. J Mol Cell Cardiol 1990;22:1187–97.
[90] Thomas C, Carr AC, Winterbourn CC. Free radical inactivation of rabbit muscle
creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-
198) iron chelates. Free Radic Res 1994;21:387–97.
[91] Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of
peroxynitrite during doxorubicin cardiomyopathy: evidence for selective im-
pairment of myoﬁbrillar creatine kinase. Br J Pharmacol 2002;135:581–8.
[92] Suzuki T, Miyauchi T. A novel pharmacological action of ET-1 to prevent the cy-
totoxicity of doxorubicin in cardiomyocytes. Am J Physiol Regul Integr Comp
Physiol 2001;280:R1399–406.
[93] Picard P, Smith PJ, Monge JC, Rouleau JL, Nguyen QT, Calderone A, et al. Coordi-
nated upregulation of the cardiac endothelin system in a rat model of heart fail-
ure. J Cardiovasc Pharmacol 1998;31(Suppl. 1):S294–7.
[94] Pieske B, Beyermann B, Breu V, Lofﬂer BM, Schlotthauer K, Maier LS, et al. Func-
tional effects of endothelin and regulation of endothelin receptors in isolated
human nonfailing and failing myocardium. Circulation 1999;99:1802–9.
[95] Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma
endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopa-
thy. Pharmacol Toxicol 2001;89:140–4.
[96] Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: thera-
peutic considerations for a novel class of cardiovascular drugs. Circulation
2000;102:2434–40.
[97] Miller WL, Cavero PG, Aarhus LL, Heublein DM, Burnett Jr JC. Endothelin-mediated
cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglyc-
erin in vivo. Am J Hypertens 1993;6:156–63.
[98] Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, et al. The
endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomy-
opathy. Cancer Res 2007;67:10428–35.
[99] Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, et al. Conditional cardiac
overexpression of endothelin-1 induces inﬂammation and dilated cardiomyopa-
thy in mice. Circulation 2004;109:255–61.
[100] Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases:
inﬂuence on cardiac form and function. Physiol Rev 2007;87:1285–342.
[101] Goetzenich A, Hatam N, Zernecke A, Weber C, Czarnotta T, Autschbach R, et al.
Alteration of matrix metalloproteinases in selective left ventricular adriamycin-
induced cardiomyopathy in the pig. J Heart Lung Transplant 2009;28:
1087–93.
1224 Y. Octavia et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 1213–1225[102] Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, et al.
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in
H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res
2006;69:736–45.
[103] Tokarska-Schlattner M, Lucchinetti E, Zaugg M, Kay L, Gratia S, Guzun R, et al.
Early effects of doxorubicin in perfused heart: transcriptional proﬁling reveals
inhibition of cellular stress response genes. Am J Physiol Regul Integr Comp Phy-
siol 2010;298:R1075–88.
[104] Singh BK, Pathan RA, Pillai KK, Haque SE, Dubey K. Diclofenac sodium, a nonse-
lective nonsteroidal anti-inﬂammatory drug aggravates doxorubicin-induced
cardiomyopathy in rats. J Cardiovasc Pharmacol Feb 2010;55(2):139–44.
[105] Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of
cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J
Clin Invest 2001;108:585–90.
[106] Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, et al. Acute doxoru-
bicin cardiotoxicity is associated with miR-146a-induced inhibition of the neur-
egulin–ErbB pathway. Cardiovasc Res 2010;87(4):656–64.
[107] Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ.
L-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes:
role of inhibition of ceramide generation. FASEB J 1999;13:1501–10.
[108] d'Anglemont de Tassigny A, Souktani R, Henry P, Ghaleh B, Berdeaux A. Volume-
sensitive chloride channels (ICl,vol) mediate doxorubicin-induced apoptosis
through apoptotic volume decrease in cardiomyocytes. Fundam Clin Pharmacol
2004;18:531–8.
[109] Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G, et al.
Pharmacological inhibition of CB1 cannabinoid receptor protects against
doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007;50:528–36.
[110] Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1
cannabinoid receptors promote oxidative stress and cell death in murine
models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes.
Cardiovasc Res 2010;85:773–84.
[111] Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and
geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol
Ther 2009;14:59–67.
[112] Torti FM, BristowMM, Lum BL, Carter SK, Howes AE, Aston DA, et al. Cardiotoxicity
of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res
1986;46:3722–7.
[113] Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed)
1982;17:101–8 10–1.
[114] Takemura G, FujiwaraH. Doxorubicin-induced cardiomyopathy from the cardiotoxic
mechanisms to management. Prog Cardiovasc Dis 2007;49:330–52.
[115] Hengel CL, Russell PA, Gould PA, Kaye DM. Subacute anthracycline cardiotoxicity.
Heart Lung Circ 2006;15:59–61.
[116] Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due
to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987;106:
814–6.
[117] Cohen M, Kronzon I, Lebowitz A. Reversible doxorubicin-induced congestive
heart failure. Arch Intern Med 1982;142:1570–1.
[118] McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity
and speciﬁcity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
Am Heart J 1983;106:1048–56.
[119] Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH,
Crijns HJ, et al. Early detection of anthracycline induced cardiotoxicity in asymp-
tomatic patients with normal left ventricular systolic function: autonomic versus
echocardiographic variables. Heart 1999;81:419–23.
[120] Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of
cardiac nuclear imaging. J Nucl Cardiol 2006;13:415–26.
[121] Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, et al. Detection of
dose response in chronic doxorubicin-mediated cell deathwith cardiac technetium
99m annexin V single-photon emission computed tomography. Mol Imaging
2008;7:132–8.
[122] Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B.
Early detection of doxorubicin cardiomyopathy using two-dimensional strain
echocardiography. Ultrasound Med Biol 2008;34:208–14.
[123] Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter Jr JJ. Dobutamine stress
echocardiography: a sensitive indicator of diminished myocardial function in
asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J
Am Coll Cardiol 1992;19:394–401.
[124] Elbl L, Hrstkova H, Chaloupka V, Novotny J, Michalek J. The evaluation of left ven-
tricular function in childhood cancer survivors by pharmacological stress echo-
cardiography. Neoplasma 2003;50:191–7.
[125] Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al.
Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardio-
graphic analysis of left ventricular ﬁlling dynamics. Am Heart J 1989;118:
92–8.
[126] Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolon-
gation of isovolumetric relaxation time as assessed by Doppler echocardiogra-
phy predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll
Cardiol 1992;20:62–9.
[127] Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The
effect of dexrazoxane on myocardial injury in doxorubicin-treated children
with acute lymphoblastic leukemia. N Engl J Med 2004;351:145–53.
[128] Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma
levels of natriuretic peptides in relation to doxorubicin-induced cardio-
toxicity and cardiac function in children with cancer. Med Pediatr Oncol
2001;37:4–9.[129] Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-
type natriuretic peptide levels after anthracycline administration. Am Heart J
1998;136:362–3.
[130] Erttmann R, Erb N, Steinhoff A, Landbeck G. Pharmacokinetics of doxorubicin in
man: dose and schedule dependence. J Cancer Res Clin Oncol 1988;114:509–13.
[131] Creech RH, Catalano RB, Shah MK. An effective low-dose adriamycin regimen as
secondary chemotherapy for metastatic breast cancer patients. Cancer 1980;46:
433–7.
[132] Schroeder PE, Hasinoff BB. Metabolism of the one-ring open metabolites of the
cardioprotective drug dexrazoxane to its active metal-chelating form in the
rat. Drug Metab Dispos 2005;33:1367–72.
[133] Hasinoff BB. The hydrolysis activation of the doxorubicin cardioprotective agent
ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Metab Dispos
1990;18:344–9.
[134] Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA. Dexrazoxane
prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial
mitochondria from genetic and functional lesions in rats. Br J Pharmacol
2007;151:771–8.
[135] Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, et al. Ab-
sence of secondary malignant neoplasms in children with high-risk acute lym-
phoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008;26:1106–11.
[136] Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al.
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syn-
drome and other secondary malignancies in pediatric Hodgkin's disease. J Clin
Oncol 2007;25:493–500.
[137] Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,
et al. American Society of Clinical Oncology 2008 clinical practice guideline up-
date: use of chemotherapy and radiation therapy protectants. J Clin Oncol
2009;27:127–45.
[138] van Acker SA, Voest EE, Beems DB, Madhuizen HT, de Jong J, Bast A, et al. Cardi-
oprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-
pretreated BALB/c mice. Cancer Res 1993;53:4603–7.
[139] van Acker FA, Hulshof JW, Haenen GR, Menge WM, van der Vijgh WJ, Bast A.
New synthetic ﬂavonoids as potent protectors against doxorubicin-induced car-
diotoxicity. Free Radic Biol Med 2001;31:31–7.
[140] van Acker SA, Kramer K, Grimbergen JA, van den Berg DJ, van der Vijgh WJ, Bast
A. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced
cardiotoxicity. Br J Pharmacol 1995;115:1260–4.
[141] van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K,
et al. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent,
does not affect the antitumor activity of doxorubicin. Clin Cancer Res
1997;3:1747–54.
[142] Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A,
et al. The effect of monohydroxyethylrutoside on doxorubicin-induced cardio-
toxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer
2007;97:1084–9.
[143] Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of
carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol
2006;48:2258–62.
[144] Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N,
Marinakis T, et al. Cardioprotective effect of metoprolol and enalapril in
doxorubicin-treated lymphoma patients: a prospective, parallel-group, random-
ized, controlled study with 36-month follow-up. Am J Hematol 2010;85:894–6.
[145] Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al. Re-
sponse of doxorubicin-induced cardiomyopathy to the current management
strategy of heart failure. J Heart Lung Transplant 2005;24:2196–201.
[146] Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-
enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet
1996;347:297–9.
[147] Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective
effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on
doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001;414:71–8.
[148] al-Shabanah O, Mansour M, el-Kashef H, al-Bekairi A. Captopril ameliorates
myocardial and hematological toxicities induced by adriamycin. Biochem Mol
Biol Int 1998;45:419–27.
[149] Sacco G, Mario B, Lopez G, Evangelista S, Manzini S, Maggi CA. ACE inhibition and
protection from doxorubicin-induced cardiotoxicity in the rat. Vascul Pharmacol
2009;50:166–70.
[150] Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR.
Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor an-
tagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxici-
ty. Pharmacol Res 2009;60:373–81.
[151] Ramond A, Sartorius E, Mousseau M, Ribuot C, Joyeux-Faure M. Erythropoietin
pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.
Exp Biol Med (Maywood) 2008;233:76–83.
[152] Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sokler M, et al. Epoetin
alfa in patients with advanced-stage Hodgkin's lymphoma: results of the ran-
domized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:
2239–45.
[153] Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibi-
tion with sildenaﬁl attenuates cardiomyocyte apoptosis and left ventricular dys-
function in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:
1601–10.
[154] Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White Jr KL, et al. Inﬂuence of
the phosphodiesterase-5 inhibitor, sildenaﬁl, on sensitivity to chemotherapy in
breast tumor cells. Breast Cancer Res Treat 2010;124:349–60.
1225Y. Octavia et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 1213–1225[155] Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, et al. Silden-
aﬁl increases chemotherapeutic efﬁcacy of doxorubicin in prostate cancer
and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 2010;107:
18202–7.
[156] Gross GJ. Evidence for pleiotropic effects of phosphodiesterase-5 (PDE5) inhibi-
tors: emerging concepts in cancer and cardiovascular medicine. Circ Res
2011;108:1040–1.
[157] Tatlidede E, Sehirli O, Velioglu-Ogunc A, Cetinel S, Yegen BC, Yarat A, et al. Res-
veratrol treatment protects against doxorubicin-induced cardiotoxicity by alle-
viating oxidative damage. Free Radic Res 2009;43:195–205.
[158] Ajijola OA, Nandigam KV, Chabner BA, Orencole M, Dec GW, Ruskin JN, et al. Use-
fulness of cardiac resynchronization therapy in the management of doxorubicin-
induced cardiomyopathy. Am J Cardiol 2008;101:1371–2.[159] Ward KM, Binns H, Chin C, Webber SA, Canter CE, Pahl E. Pediatric heart trans-
plantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart
Lung Transplant 2004;23:1040–5.
[160] van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline deri-
vates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst
Rev 2010:CD005006.
[161] Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al.
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J
Clin Oncol 2007;25:3859–65.
[162] Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al.
Cardiovascular side effects of cancer therapies: a position statement from the
Heart Failure Association of the European Society of Cardiology. Eur J Heart
Fail 2011;13:1–10.
